Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma

Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk factors for developing hepatocellular carcinoma (HCC). The hepatocarcinogenic potential of these viruses is mediated through a wide range of mechanisms, including the induction of chronic inflammation a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saleh A. Alqahtani, Massimo Colombo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	HCC HBC HCV hepatocellular carcinoma prevention Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/8429602c2ddf40bd9c18d7d316a6e1ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8429602c2ddf40bd9c18d7d316a6e1ac
record_format	dspace
spelling	oai:doaj.org-article:8429602c2ddf40bd9c18d7d316a6e1ac2021-11-25T17:11:23ZTreatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma10.3390/cells101130912073-4409https://doaj.org/article/8429602c2ddf40bd9c18d7d316a6e1ac2021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3091https://doaj.org/toc/2073-4409Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk factors for developing hepatocellular carcinoma (HCC). The hepatocarcinogenic potential of these viruses is mediated through a wide range of mechanisms, including the induction of chronic inflammation and oxidative stress and the deregulation of cellular pathways by viral proteins. Over the last decade, effective anti-viral agents have made sustained viral suppression or cure a feasible treatment objective for most chronic HBV/HCV patients. Given the tumorigenic potential of HBV/HCV, it is no surprise that obtaining sustained viral suppression or eradication proves to be effective in preventing HCC. This review summarizes the mechanisms by which HCV and HBV exert their hepatocarcinogenic activity and describes in detail the efficacy of anti-HBV and anti-HCV therapies in terms of HCC prevention. Although these treatments significantly reduce the risk for HCC in patients with chronic viral hepatitis, this risk is not eliminated. Therefore, we evaluate potential strategies to improve these outcomes further and address some of the remaining controversies.Saleh A. AlqahtaniMassimo ColomboMDPI AGarticleHCCHBCHCVhepatocellular carcinomapreventionBiology (General)QH301-705.5ENCells, Vol 10, Iss 3091, p 3091 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HCC HBC HCV hepatocellular carcinoma prevention Biology (General) QH301-705.5
spellingShingle	HCC HBC HCV hepatocellular carcinoma prevention Biology (General) QH301-705.5 Saleh A. Alqahtani Massimo Colombo Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
description	Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk factors for developing hepatocellular carcinoma (HCC). The hepatocarcinogenic potential of these viruses is mediated through a wide range of mechanisms, including the induction of chronic inflammation and oxidative stress and the deregulation of cellular pathways by viral proteins. Over the last decade, effective anti-viral agents have made sustained viral suppression or cure a feasible treatment objective for most chronic HBV/HCV patients. Given the tumorigenic potential of HBV/HCV, it is no surprise that obtaining sustained viral suppression or eradication proves to be effective in preventing HCC. This review summarizes the mechanisms by which HCV and HBV exert their hepatocarcinogenic activity and describes in detail the efficacy of anti-HBV and anti-HCV therapies in terms of HCC prevention. Although these treatments significantly reduce the risk for HCC in patients with chronic viral hepatitis, this risk is not eliminated. Therefore, we evaluate potential strategies to improve these outcomes further and address some of the remaining controversies.
format	article
author	Saleh A. Alqahtani Massimo Colombo
author_facet	Saleh A. Alqahtani Massimo Colombo
author_sort	Saleh A. Alqahtani
title	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
title_short	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
title_full	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
title_fullStr	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
title_full_unstemmed	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
title_sort	treatment for viral hepatitis as secondary prevention for hepatocellular carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8429602c2ddf40bd9c18d7d316a6e1ac
work_keys_str_mv	AT salehaalqahtani treatmentforviralhepatitisassecondarypreventionforhepatocellularcarcinoma AT massimocolombo treatmentforviralhepatitisassecondarypreventionforhepatocellularcarcinoma
_version_	1718412660012220416

Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma

Ejemplares similares